We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Allergan will pay $250 million to acquire the worldwide rights to two of Merck’s investigational small molecule oral calcitonin gene-related peptide (CGRP) antagonists for use against migraines. Read More
AstraZeneca and Cephalon have agreed to pay $54 million, plus interest, to settle allegations that they knowingly underpaid quarterly rebates owed to states under the Medicaid program. Read More
After nearly 25 years of trying to reach biologics manufacturer Chembiomed but getting no response, the FDA today revoked the Canadian firm’s license. Read More
The FDA is offering a four-month grace period to retail and hospital pharmacies that do not act as wholesale distributors to electronically exchange drug transaction information. Read More
The FDA is adding plasma fibrinogen as a prognostic biomarker for patient selection in clinical trials involving chronic obstructive pulmonary disease and a high risk of death. Read More
A recent survey showing that drug company executives are often unaware of problems faced by their quality control units may point to an overlooked contributing factor in FDA warning letters, an expert says. Read More
A Luxembourg-based nonprofit set up by European pharma groups is one step closer to launching a counterfeit drug repository system, having finalized contracts with three software firms to help implement the system. Read More